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ABSTRACT  
As -carboxy nucleoside phosphonates (-CNPs) have demonstrated a novel mode of action of 
HIV-1 reverse transcriptase inhibition, structurally related derivatives were synthesized, namely 
the malonate 2, the unsaturated and saturated bisphosphonates 3 and 4, respectively and the 
amide 5. These compounds were evaluated for inhibition of HIV-1 reverse transcriptase in cell-
free assays. The importance of the -carboxy phosphonoacetic acid moiety for achieving reverse 
transcriptase inhibition, without the need for prior phosphorylation, was confirmed. The 
malonate derivative 2 was less active by two orders of magnitude than the original -CNPs, 
while displaying the same pattern of kinetic behavior; interestingly the activity resides in the 
“L”-enantiomer of 2, as seen with the earlier series of -CNPs. A crystal structure with an 
RT/DNA complex at 2.95 Å resolution revealed the binding of the “L”-enantiomer of 2, at the 
polymerase active site with a weaker metal ion chelation environment compared to 1a (T--
CNP) which may explain the lower inhibitory activity of 2. 
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INTRODUCTION 
World Health Organization statistics state that 2.1 million people were infected with the human 
immunodeficiency virus (HIV) in 2013, bringing the number of people now living with the virus 
to approximately 35 million.1 While a recent study claims that the retrovirus is slowly becoming 
milder in its virulence due to a number of factors (i.e. mutations, increased drug resistance),2 
other work has predicted increasing rates of disease transmission.3 Thus, the quest for novel 
drugs that possess anti-HIV properties (in terms of mechanism of action, resistance profile, 
inhibition potency, side effects profile, etc.) is of utmost importance. 
Recently, we disclosed the synthesis and evaluation of a novel class of -carboxy nucleoside 
phosphonates (-CNPs) 1 which exhibit potent HIV-1 reverse transcriptase (RT) inhibitory 
properties in cell free assays (Figure 1).4,5 Most importantly, these compounds unlike nucleoside-
analog drugs do not require intracellular activation (i.e. phosphorylation) in order to display 
activity against the virus-encoded RT. Interestingly, the -carboxy phosphonate moiety is acting 
as a triphosphate mimic as demonstrated by crystallographic analysis. In fact, the carboxylate 
oxygen mimics the interaction of a nucleotide α-phosphate with a Mg2+ ion, while the two 
phosphonate oxygens of the α-CNPs mirror the interaction of - and -phosphate oxygens of 
nucleotides with the same Mg2+ ion.5  
 
Figure 1. -carboxynucleoside phosphonate (-CNP) 
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Intrigued by this novel mode of action, we decided to investigate the influence of altering the 
carboxy phosphonate group on HIV-1 RT inhibition while keeping the remainder of the α-CNP 
structure intact. Accordingly, the malonate 2, bisphosphonates 3 and 4 and the amide 5 were 
chosen as potential targets. In addition, previously synthesized esters4 6 and 7 were also included 
in the evaluation (Figure 2). The key aspect we wish to investigate is whether the activity of the 
-carboxy phosphonate could be mimicked through the diacid 2 or the bisphosphonates, or 
indeed whether the carboxylic acid could be replaced by a primary amide in 5 or an ester in 6 
and 7, thereby determining whether the ionizable acid is essential, or whether the metal ion 
coordinating ability of a primary amide is sufficient to maintain the inhibitory activity of the -
CNPs against HIV-1 RT. 
 
Figure 2. Targets selected for HIV-RT inhibition 
Compound 2 possesses a diacid moiety which is related to the diketoacid (DKA) structural 
feature which has been implicated in the activity of HIV-1 integrase (IN) inhibitors,6 namely 
raltegravir 8,7,8 elvitegravir9 9 and the recently approved dolutegravir 10.10 The planar geometry 
of the DKA moiety is believed to facilitate chelation of two Mg2+ ions in the active site. 11,12 
5 
 
 5 
Compound 11 exhibits moderate inhibition of wild-type HIV-1 RT polymerase.13 The 
bisphosphonate moiety of 3 and 4 is a key structural motif in compounds such as pamidronic 
acid 12 which is used in the treatment of bone-related diseases.14 Recently, advocacy for their 
use in the treatment of HIV-related osteoporosis has increased.15 Inorganic pyrophosphate (PPi) 
13 is formed during the catalytic cycle of nucleotide monophosphate incorporation into a 
growing nucleotide copolymer and it can induce a conformational change in polymerases from 
an open to a closed conformation by binding to the active site.16 Investigations have centered on 
the ability of bioisosteres of PPi to inhibit HIV-1 RT. Foscarnet (phosphonoformic acid)17-19 14 
acts by trapping the pre-translocational state of HIV-1 RT, and while phosphonoacetic acid 
(PAA) 15 is a potent anti-herpetic agent, it is virtually ineffective against HIV.20-22 
Oxophosphonoacetate 16 is an inhibitor of some nucleic acid polymerases.22,23 
Carbonylbisphosphonate (COBP) 17, first isolated by Quimby24 and further investigated by 
McKenna, is efficient at inhibiting HIV-1 RT.23,25,26 Compound 18 is non-inhibitory towards 
HIV-1 RT, however, and despite extensive efforts having been devoted to the synthesis of small 
molecule substituted derivatives of 15 and 18, these efforts have usually resulted in less effective 
HIV-1 RT inhibitors than foscarnet.26 The preparation and characterization of AZT 5´-COBP 19 
has been described, but no biological data has been reported.27 More recently, purine-like 
bisphosphonates 20 and 21 have been shown to inhibit HIV-1 RT-catalyzed synthesis.28 Finally, 
the amide 5 is reminiscent of anti-HIV pronucleosides 22 and 23 documented by Shirokova, with 
22 inhibiting virus replication by 90% at significantly lower concentrations than AZT.29 
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In this context, evaluation of the properties of the malonate 2, bisphosphonates 3 and 4 and the 
amide 5 was warranted. 
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RESULTS AND DISCUSSION 
Scheme 1. Synthesis of malonate derivative 2.a 
 
aConditions: (a) ABSA, K2CO3, MeCN, 48 h; (b) 26, Rh2(OAc)4, C6H6, 80 °C, 12 h; (c) 
thymine, Pd(dba)2, dppb, Na2CO3, aq. MeCN, Microwave (MW) 50 °C; (d) H2, Pd/C 1 atm, 
MeOH, 15 h. 
The synthesis of 2 was accomplished in four steps from commercially available dibenzyl 
malonate (Scheme 1). Diazo transfer to 24 was achieved in the presence of 4-
acetamidobenzenesulfonyl azide (ABSA) to give the novel dibenzyl 2-diazomalonate 25. 
Building upon our previous work with rhodium insertion reactions,30,31 rhodium (II)-catalyzed 
OH insertion of 25 with the allylic alcohol 2632-34 furnished 27 in 48% yield.  Thymine base 
insertion of 27 in a palladium-catalyzed Tsuji-Trost reaction35 was carried out under microwave 
conditions to afford 28. Finally, simultaneous hydrogenation of the cyclopentyl alkene and 
hydrogenolysis of the benzyl esters of 28 was achieved under atmospheric pressure of hydrogen 
in the presence of Pd/C to provide the target malonate 2 in racemic form (57% yield). Despite 
our initial concerns that 2 may undergo decarboxylation during isolation or upon standing, a 
solution of 2 in MeOH-d4 was found to be stable at room temperature for up to 6 months. We 
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have already described the synthesis and characterization of the decarboxylated compound 294 
and were unable to detect its presence by NMR in the solution of 2 after 6 months. Furthermore, 
storage of malonate 2 in solid state proved easier than anticipated, with little or no evidence of 
decarboxylation on storage for several months.  
The malonates were also synthesized in both enantiopure forms 2a and 2b. This was achieved 
using the same sequence of reactions described for the racemic series starting from the 
commercially available enantiomers of the acetoxy alcohol 26a and 26b (Scheme 2). Yields were 
consistent with those obtained for the racemic series. 
Scheme 2. Synthesis of enantiopure forms of 2.a 
 
aConditions: (a) 25, Rh2(OAc)4, C6H6, 80 °C; (b) thymine, Pd(dba)2, dppb, Na2CO3, aq. 
MeCN, MW 50 °C; (c) H2, Pd/C 1 atm, MeOH. 
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Scheme 3. Synthesis of bisphosphonates 3 and 4.a 
 
aConditions: (a) 26, Rh2(tfacam)4, C6H6, 80 °C; (b) thymine, Pd(dba)2, dppb, Na2CO3, aq. 
MeCN, 50 °C MW; (c) (i) TMSBr, lutidine, MeCN, MW 50 °C, (ii) MeOH/H2O 1 h, (iii) 
charcoal chromatography; (d) H2, Pd/C 1 atm, MeOH, 15 h; (e) (i) TMSBr, MeCN, MW 50 °C, 
(ii) MeOH/H2O 1 h, (iii) charcoal chromatography. 
A similar strategy was employed for the preparation of the racemic bisphosphonates 3 and 4 
(Scheme 3).  It was envisaged that O-H insertion of tetraethyl diazomethylenebisphosphonate 
3036 with alcohol 26 would require more forcing conditions than the analogous reaction with 
diazomalonate 25. Therefore, in this case, the more active rhodium trifluoroacetamide was 
employed as catalyst and it was added portionwise over the course of the reaction.  Gratifyingly, 
under these conditions, the O-H insertion product 31 was obtained in 87% yield after correction 
for the recovered starting material 26.  Introduction of thymine under Tsuji-Trost conditions 
proceeded efficiently in the microwave to afford bisphosphonate 32 in 48% yield.   Finally, 
cleavage of the phosphonate ethyl esters of 32 was achieved using bromotrimethylsilane 
(TMSBr) in the presence of lutidine and the desired unsaturated bisphosphonate 3 was isolated as 
its ammonium salt in 84% yield following charcoal chromatography. Interestingly both the O-H 
insertion and base insertion steps were effective despite the alteration from the phosphonoacetic 
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acid moiety to the malonate and bisphosphonate confirming the generality of the synthetic route 
developed for the α-CNPs. Palladium mediated hydrogenation of 32 afforded 33 and subsequent 
hydrolysis of the phosphonate esters of 33 followed by charcoal chromatography gave 4 as the 
ammonium salt. 
Scheme 4. Synthesis of amide 5.a 
 
aConditions: (a) 7N NH3 in MeOH, 65 h; (b) (i) TMSBr, MeCN, MW 50 °C, (ii) MeOH/H2O 
30 min, (iii) charcoal chromatography. 
The synthesis of the amide (Scheme 4) derivative 5 commenced with the methyl ester 34, which 
was also a key intermediate in the synthesis of -CNPs which we described earlier.4 Aminolysis 
of the carboxy methyl ester was achieved by stirring 34 for 65 h in a 7N solution of ammonia in 
methanol to afford 35 in 35% yield.  The low yield may be explained by the fact that attack at the 
phosphonate ester groups is also possible under the reaction conditions. Following isolation of 35 
by chromatography, the phosphonate esters were hydrolyzed and 5 was isolated as the 
ammonium salt in 70% yield. 
The eight structurally related compounds (malonates 2, 2a, 2b, bisphosphonates 3 and 4, amide 5 
and esters 6 and 7) were evaluated for their inhibitory activity using a cell-free HIV-1-RT assay 
and the results compared with those obtained for the parent -CNPs (1, 1a, 1b and 36).4,5 Poly 
rA.oligo dT was used as the homopolymeric template/primer, and [3H]dTTP as the radiolabeled 
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substrate. The IC50 (50% inhibitory concentration) was determined as the compound 
concentration required to inhibit RT-catalysed dTTP incorporation into the growing DNA strain. 
For the parent α-CNPs, our research has already shown that the “L”-enantiomer 1a is the more 
active of the two enantiomeric compounds (Table 1, Entry 2 vs. 3). The effect of unsaturation of 
the racemic α-CNPs (i.e. compound 36 compared to 1) is to decrease the activity by ~ 5-fold 
(Table 1, Entry 4 vs. 1).4 
Importantly, the presence of a methyl ester in place of the carboxylic acid effectively shuts down 
activity as evidenced by results obtained for 6 and 7. This effect is further highlighted by the 
amide 5 which shows poor, if any, relevant inhibitory activity against HIV-1 RT (Table 1, Entry 
12). The lack of significant activity of the amide and esters 6 and 7 confirms that two ionizable 
moieties are required to efficiently coordinate the magnesium ions to display efficient RT 
inhibition. 
The unsaturated bisphosphonate 3 is poorly active (IC50: 204 µM) (Table 1, Entry 10), while the 
saturated analog 4 is similarly ineffective to inhibit HIV-1 RT. 
The racemic malonate 2 (Table 1, Entry 7) displays an activity approximately 100-fold less than 
observed for racemic α-CNP 1 (Table 1, Entry 1). However, the results obtained for the 
enantiopure malonates are interesting in terms of mirroring the behavior observed for the α-
CNPs. The malonate 2a (“L”-enantiomer) is 2-fold more active (IC50: 20 µM) than the racemic 
mixture 2 (IC50: 42 µM) [Table 1, Entry 8 vs. Entry 7], while the “D”-enantiomer lacked any 
relevant inhibitory activity against HIV-1 RT (IC50: > 640 µM) [Table 1, Entry 9]. Such a 
selective activity profile (predominant activity by the “L”-enantiomer) has also been observed 
for the prototype α-CNPs as mentioned above. Also, it should be noticed that the malonate 2a, as 
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also found for the α-CNPs, does not need metabolic conversion to a higher phosphate metabolite 
to exert anti-HIV-1 RT activity. 
Table 1. Inhibitory activity of the compounds against HIV-1 RT 
 
aBase = Thymine. bFifty percent inhibitory concentration, or compound concentration required 
to inhibit HIV-RT-catalyzed incorporation of [3H]dNTP in the homopolymeric template/primer. 
Data are the mean  SD of at least 3 to 4 independent experiments. cSynthesis (1, 1a, 1b, 36, 6 
and 7) and IC50 data (1, 1a, 1b, 36) see Ref 4. 
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Finally, when the active malonate enantiomer 2a was investigated for its kinetic interaction with 
HIV-1 RT, reciprocal velocity versus substrate Lineweaver-Burk plots revealed a competitive 
inhibition of the enzyme by 2a with respect to the natural substrate dTTP (Fig. 3). The inhibitory 
constant Ki of 2a was 6.6 µM. The Km of dTTP was 5.9 µM. This kinetic behavior was also 
earlier observed for the prototype α-CNP compound 1.5 
 
Figure 3. Lineweaver-Burk plots for the inhibition of HIV-1 RT by compound 2a. 
A crystal structure of 2a was determined in complex with HIV-1 RT/38-mer DNA aptamer;37 the 
38-mer DNA template-primer aptamer mimics the binding of a double-stranded (ds) DNA at the 
polymerase active site, and contains a single-stranded (ss) DNA template overhang.37  The pre-
formed crystals were soaked in a 2mM solution of 2a for the formation of RT/DNA/2a ternary 
complex, and the crystal structure revealed the binding of 2a at the polymerase active site (Fig. 
4).  The structure contains two copies of RT/DNA, and only the first one has ordered electron 
density for 2a. The general mode of binding of 2a is similar to that of 1a (T--CNP).5 The 
thymine base of 2a is base-paired with the adenine base of 1st overhang nucleotide, and the 
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cyclopentyl ring is positioned over the aromatic side chain of Tyr115; both interactions of 2a are 
analogous to those observed with the binding of 1a (T--CNP) to RT.  However, metal chelation 
at the polymerase active site differs for the two inhibitors.  One oxygen from each of the 
carboxyl groups of 2a chelate with a Mg2+ ion (metal B) at the polymerase active site, and the 
ion also chelates to the main-chain carbonyl oxygen of V111 and a side-chain oxygen of the 
catalytic aspartate Asp185.  Interestingly, the catalytic residue Asp110 is switched away from the 
active site, and does not participate in the Mg2+ chelation in the structure of the 2a complex.  
Presumably, the chelation of the malonate group of 2a is not compatible with the chelation of all 
three catalytic aspartates (Asp110, Asp185, and Asp186), which is observed for the binding of a 
dNTP and for 1a (T--CNP).5 The binding of 2a involves only 4 observed chelations for the 
Mg2+ ion B in contrast to a complete octahedral coordination environment when T--CNP 1a 
was bound.  We expect that two water molecules might be involved to complete the coordination 
environment for the Mg2+ ion when 2a is bound, however, no clear electron density was 
observed for any potentially chelating ordered water molecule in the crystal structure of 
RT/DNA/2a complex.  In summary, the structure suggests that the significantly perturbed 
coordination environment due to the malonate group is a primary contributor to the lower RT 
inhibition by 2a compared to the inhibition by 1a (T--CNP). Thereby, a potent CNP class of 
nucleoside competing RT inhibitor (NcRTI) should chelate the catalytic Mg2+ ions in a mode 
analogous to that observed in the chelation of a dNTP substrate. 
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Figure 4. Structure of 2a in complex with HIV-1 RT/DNA. (a) 2.95 Å resolution electron 
density map defines the binding of 2a (green) at the polymerase active site of RT.  The inhibitor 
binding affinity has contributions from the base pairing (gray dotted lines) and base stacking, 
hydrophobic stacking of the cyclopentyl ring with the aromatic side chain of Tyr115, and the 
chelation with a Mg2+ ion at the polymerase active site (black dotted lines).  The chelation 
environment for 2a is significantly different from the octahedral coordination environment 
observed for 1a (T--CNP) (b). 
When evaluated for their anti-HIV activity in cell culture, the compounds were found to be 
antivirally inactive at concentrations up to 100 µM. Also, they were devoid of any significant 
cytotoxicity. Presumably, the compounds might be too polar to be efficiently taken up by intact 
cells. Therefore, a prodrug approach should be considered to deliver the active molecules 
directly into the intact virus-infected cells. The design and synthesis of such prodrug derivatives 
are currently under investigation. 
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CONCLUSION 
We designed and synthesized structurally related analogues of -CNPs and investigated their 
ability to inhibit HIV-1 RT in cell-free enzyme assays. The amide derivative 5 was virtually 
inactive while the bisphosphonates 3 and 4 also exhibited poor inhibition of HIV-1 RT. The 
requirement for two ionizable functional groups to be present in order to exhibit inhibition was 
demonstrated through the lack of activity of both esters 6 and 7 and also the amide 5.  The 
malonate 2 was the most active of the compounds albeit significantly less active that the original 
-CNPs. Enantiopure forms of the malonate behaved in a similar fashion to the parent -CNP in 
that the activity resides in the “L”-enantiomer. The crystal structure together with the RT 
inhibition data confirms the significance of the α-carboxy phosphonoacetic acid moiety in 
affording efficient RT inhibition without need for any further phosphorylation. 
EXPERIMENTAL SECTION 
General Information 
Solvents were distilled prior to use as follows: dichloromethane was distilled from phosphorus 
pentoxide; ethyl acetate was distilled from potassium carbonate. Benzene was dried before use 
with activated 4Å molecular sieves. For O-H and base insertion reactions, solvents were 
degassed by purging with nitrogen for 5 min. Organic phases were dried using anhydrous 
magnesium sulfate. All commercial reagents were used without further purification. Microwave 
reactions were carried out using a CEM Discover in conjunction with Synergy software, reaction 
temperatures were measured by IR sensor. 1H, 13C, and 31P spectra were recorded at 20 °C on 
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300 or 400 MHz spectrometers. Chemical shifts are given in ppm relative to tetramethylsilane 
(TMS) as an internal standard. 31P chemical shifts are referenced to H3PO4 (external standard). 
Coupling constants (J) are given in hertz (Hz). In some cases the signal for the PCH was not 
observed in the carbon-13 NMR spectrum. Infrared spectra were recorded neat on a PerkinElmer 
Spectrum Two; operating in Universal Attenuated Total Reflectance (UATR) mode. Melting 
points were measured using a capillary melting point apparatus and are not corrected. Optical 
rotations were measured at 20 °C at 589 nm in a 10 cm cell; concentrations (c) are expressed in 
g/100 ml, [α] is expressed in units of 10−1 deg cm2 g−1. Low resolution mass spectra were 
recorded in electrospray ionization (ESI) mode, high resolution mass spectra (HRMS) were 
recorded on a Time of Flight spectrometer in electrospray ionization (ESI) mode. Column 
chromatography was performed using silica gel 60. Thin layer chromatography (TLC) was 
carried out on precoated silica gel plates (60 PF254). Visualization was achieved by UV (254 
nm) detection and/or staining with vanillin or permanganate. Compounds 6,4 7,4 2632-34 and 3036 
were prepared by literature methods. 
Reverse transcription assays 
HIV-I RT assays were carried out in the presence of homopolymeric template/primers. Poly(A) 
and dT12-18 were from Pharmacia (Uppsala, Sweden). To prepare the template/primers for the 
RT experiments, 0.15 mM poly(A) was mixed with an equal volume of 0.0375 mM oligo(dT). 
The reaction mixture (50 µl) contained 50 mM Tris.HC1 pH 7.8, 5 mM dithiothreitol, 300 mM 
glutathione, 500 µM EDTA, 150 mM KCl, 5 mM MgCl2, 1.25 µg of bovine serum albumin, an 
appropriate concentration of the tritium-labeled substrate [CH3-3H]dTTP (1 µCi/assay; 60 
Ci/mmole), a fixed concentration of the template/primer poly(A).oligo(dT) (0.015 mM), 0.06% 
Triton X-100, 10 µl of -CNP inhibitor solution (containing various concentrations of the 
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compounds), and 1 µl (being equivalent to 1 pmole (0.13 ng) enzyme or 20 pM final 
concentration) of the HIV-1 RT preparation. The reaction mixtures were incubated at 37°C for 
30 minutes, at which time 100 µl of calf thymus DNA (150 µg/ml), 2 ml of Na4P2O7 (0.1 M in 1 
M HCl), and 2 ml of trichloroacetic acid (10% v/v) were added. The solutions were kept on ice 
for 30 minutes, after which the acid-insoluble material was washed and analyzed for 
radioactivity. For the experiments in which the 50% inhibitory concentration (IC50) of the test 
compounds was determined, a fixed concentration of 1.25 µM [3H]dTTP was used. For the 
experiments in which the kinetic nature of the malonate derivative 2a was determined, different 
[3H]dTTP concentrations (3, 4, 6, 10, 20 and 40 µM) were used in the presence of different 
inhibitor concentrations (75, 30 and 15 µM). The activity values were plotted in a reciprocal 
velocity versus substrate Lineweaver-Burk diagram. It should be emphasized that under the 
experimental conditions, the RT reaction was linear for up to 30 min, and at the end of the 
incubation period, less than 5% of the available dTTP substrate was consumed (incorporated). 
X-ray crystallography 
The crystals of RT/38-mer DNA aptamer complex were obtained using a previously defined 
protocol.37 A crystal soaked in a solution containing 2.5mM of 2 and 20mM MgCl2 for 15 
minutes diffracted the best up to 2.95Å resolution (Supplementary Information Table-1). X-ray 
data were collected at APS 23ID-D beam line.  Due to anisotropy diffractions and radiation 
sensitivity of the crystal, the collected data is only 84.8% complete with 87.5% in the highest 
resolution cell.  The dataset was processed using Mosflm38 and the RT/38-mer DNA aptamer 
binary complex structure (PDB Id. 5D3G) was used as the starting model for obtaining the 
molecular replacement solution.  There are two copies of RT/DNA complex in the asymmetric 
unit. The difference (|Fo| - |Fc|) electron density map clearly revealed the binding of the 
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compound 2 at the polymerase active site of one of two RT/DNA copies in the asymmetric unit.  
The crystallography software Phenix39 and Coot40 were used for structure refinement and model 
building, respectively.  Final refinement statistics are listed in Supplementary Information Table-
1, and the coordinates and structure factors are deposited in PDB with the accession number 
5HLF. 
Synthesis 
Dibenzyl 2-diazomalonate (25) 
Potassium carbonate (3.34 g, 0.024 mol) was added to a solution of dibenzyl malonate (3.19 g, 
0.011 mol) and 4-acetamidobenzenesulfonyl azide (2.65 g, 0.011 mol) in MeCN (50 mL). The 
resulting suspension was stirred for 24 h at room temperature, filtered and concentrated in vacuo. 
The residue was taken up in DCM (50 mL), and the solution was washed with aqueous NaOH 
(50 mL, 1M), water (50 mL) and brine (50 mL), dried (MgSO4) and concentrated in vacuo. The 
residue was purified by chromatography (SiO2, ether) to afford the title compound as a white 
solid (2.21 g, 64%): m.p. = 56-57 °C; max/cm-1: 3407, 2940, 2145, 2129, 1758, 1708, 1690; 1H 
NMR (300 MHz, CDCl3) δ: 5.27 (s, 2H), 7.29-7.39 (m, 5H); 13C NMR (75.5 MHz, CDCl3) δ: 
67.1, 128.2, 128.4, 128.6, 135.3, 160.8; signal for CN2 not seen; Anal. calcd for C17H14N2O4: C. 
65.80; H, 4.55; N, 9.03. Found: C, 65.82; H, 4.62; N, 8.83; HRMS (ES+): calcd for C17H15N2O4 
(M+H)+ 311.1032, found 311.1021; MS (ES+) m/z: 311 (M + H)+. 
(−)-(1S, 4R)-Dibenzyl 2-[(1-acetoxycyclopent-2-en-4-yl)oxy]malonate (27a) 
Rhodium(II) acetate (15 mg, 0.033 mmol, 1 mol%) was added to a degassed solution of (1S,4R)-
cis-4-hydroxy-2-cyclopentenyl acetate 26a (0.50 g, 3.52 mmol) and 25 (1.20 g, 3.87 mmol) in 
benzene (25 mL). The reaction mixture was stirred while heating under reflux for 24 h under a 
nitrogen atmosphere. The mixture was filtered, concentrated and the residue purified by 
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chromatography (SiO2, 20% ethyl acetate/hexane) to give (−)-(1S, 4R)-27a as a pale yellow oil 
(0.82 g, 56%): max/cm-1: 2925, 1730, 1608, 1587, 1235; [α]
20
D
  - 24.38 (c 0.08, CHCl3); 1H NMR 
(300 MHz, CDCl3) δ: 1.73-1.84 (m, 1H), 1.99 (s, 3H), 2.67-2.81 (m, 1H), 4.62-4.72 (m, 2H), 
5.19 (s, 4H), 5.39-5.47 (m, 1H), 5.94-6.16 (m, 2H), 7.19-7.41 (m, 10H); 13C NMR (75.5 MHz, 
CDCl3) δ: 21.0, 37.1, 67.6, 76.2, 76.8, 82.9, 128.3, 128.53, 128.59, 134.3, 134.8, 135.0, 166.6, 
170.6; HRMS (ES+): calcd for C24H24NaO7 (M+Na)
+ 447.1420, found 447.1426. 
(+)-(1R, 4S)-Dibenzyl 2-[(1-acetoxycyclopent-2-en-4-yl)oxy]malonate (27b) 
Synthesized following the procedure described for 27a using: rhodium(II) acetate (15 mg, 0.033 
mmol, 1 mol%), (1R,4S)-cis-4-hydroxy-2-cyclopentenyl acetate 26b (0.50 g, 3.52 mmol) and 25 
(1.20 g, 3.87 mmol). Purification by chromatography (SiO2, 20% ethyl acetate/hexane) afforded 
(+)-(1R, 4S)-27b as a colorless oil (0.65 g, 43%): [α]
20
D
  + 20.00 (c 0.05, CHCl3). 
cis-Dibenzyl 2-[(1-acetoxycyclopent-2-en-4-yl)oxy]malonate (27) 
Synthesized following the procedure described for 27a using: rhodium(II) acetate (15 mg, 0.033 
mmol, 0.8 mol%) , cis-4-hydroxy-2-cyclopentenyl acetate 26 (0.58 g, 4.08 mmol) and 25 (1.40 g, 
4.51 mmol). Purification by chromatography (SiO2, 20% ethyl acetate/hexane) gave 27 as a pale 
yellow oil (0.56 g, 32%, 48% when corrected for recovered alcohol 26). 
 (−)-(1S, 4R)-Dibenzyl 2-[(1-thymin-1-yl-cyclopent-2-en-4-yl)oxy]malonate (28a) 
A microwave vial containing a degassed suspension of thymine (190 mg, 1.51 mmol) and 
sodium carbonate (115 mg, 1.07 mmol) in water (1 mL) and acetonitrile (1 mL) was heated 
under microwave conditions (50°C, 200 W) for 30 min. A degassed solution of (−)-(1S, 4R)-27a 
(420 mg, 0.99 mmol) in acetonitrile (1 mL), bis(dibenzylideneacetone)palladium(0) Pd(dba)2 (30 
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mg, 5 mol%) and 1,4-bis(diphenylphosphino)butane (dppb) (40 mg, 9 mol%) was added to the 
vial. The resulting solution was irradiated (50°C, 200 W) for 30 min whereupon a second portion 
of Pd(dba)2 (30 mg) and dppb (40 mg) was added followed by irradiation (50°C, 200 W) for a 
further 30 min. The reaction mixture was cooled to room temperature, gravity filtered and 
concentrated under vacuum to give a purple residue which was purified by chromatography 
(SiO2, 3% methanol/dichloromethane) to afford compound (−)-(1S, 4R)-28a as an oil (52 mg, 
11%): max/cm-1: 3177, 3034, 2924, 1762, 1742, 1686; 1H NMR (300 MHz, CDCl3) δ: 1.63-1.78 
(m, 1H), 2.64-2.86 (m, 1H), 4.56-4.67 (m, 1H), 4.71 (s, 1H), 5.06-5.32 (m, 4H), 5.55-5.75 (m, 
1H), 5.80-5.96 [m, 1H), 6.15-6.29 (m, 1H), 7.21-7.39 (m, 11H), 9.31-9.52 (bs, 1H); 13C NMR 
(75.5 MHz, CDCl3) δ: 12.3, 37.2, 57.7, 67.8, 77.9, 83.4, 111.6, 128.41, 128.44, 128.63, 128.64, 
128.69, 134.4, 134.65, 134.69, 135.9, 137.1, 151.1, 164.0, 166.1, 166.3; HRMS (ES+): calcd for 
C27H27N2O7 (M+H)
+ 491.1818, found 491.1829; MS (ES+) m/z: 491 (M + H)+. 
(+)-(1R, 4S)-Dibenzyl 2-[(1-thymin-1-yl-cyclopent-2-en-4-yl)oxy]malonate (28b) 
Prepared following the procedure described for 28a using: thymine (190 mg, 1.51 mmol), 
sodium carbonate (115 mg, 1.07 mmol), (+)-(1R, 4S)-27b (420 mg, 0.99 mmol), Pd(dba)2 (30 
mg, 5 mol%) and dppb (40 mg, 9 mol%). Purification by chromatography (SiO2, 3% 
methanol/dichloromethane) gave (+)-(1R, 4S)-28b as an oil (18 mg, 4%). 
cis-Dibenzyl 2-[(1-thymin-1-yl-cyclopent-2-en-4-yl)oxy]malonate (28) 
Prepared following the procedure described for 28a using: thymine (160 mg, 1.27 mmol), 
sodium carbonate (97 mg, 0.92 mmol), 27 (355 mg, 0.84 mmol), Pd(dba)2 (25 mg, 5 mol%) and 
dppb (35 mg, 10 mol%). Purification by chromatography afforded compound 28 as an oil (25 
mg, 6%). 
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(+)-(1R, 4S)- 2-[(1-thymin-1-yl-cyclopentan-4-yl)oxy]malonic acid (2a) 
A mixture of (−)-(1S, 4R)-28a (30 mg, 0.061 mmol) and palladium on carbon (10 mg, 10%) in 
methanol (10 mL) was stirred under a balloon of hydrogen at atmospheric pressure for 24 h at 
room temperature. The mixture was filtered on Celite and the cake was rinsed with methanol. 
The filtrate was concentrated to give (+)-(1R, 4S)-2a (12 mg, 63%): [α]
20
D
  + 4.17 (c 0.24, 
MeOH); 1H NMR (300 MHz, MeOH-D4) δ: 1.48-2.15 (m, 8H), 2.19-2.36 (m, 1H), 4.02-4.17 (m, 
1H), 4.55 (s, 1H), 5.01-5.18 (m, 1H), 7.88 (s, 1H); 13C NMR (75.5 MHz, MeOH-d4) δ: 10.8, 
29.7, 30.7, 37.8, 53.6, 76.5, 80.5, 110.7, 139.2, 151.8, 165.1, 169.0; HRMS (ES+): calcd for 
C13H17N2O7 (M+H)
+ 313.1036, found 313.1030; MS (ES+) m/z: 313 (M + H)+. 
 
 
(−)-(1S, 4R)- 2-((1-thymin-1-yl-cyclopentan-4-yl)oxy)malonic acid (2b) 
Synthesized using procedure described for 2a using: (+)-(1R, 4S)-28b (25 mg, 0.051 mmol) and 
palladium on carbon (10 mg, 10%) to give (−)-(1S, 4R)-2b (13 mg, 82%): [α]
20
D
  - 6.67 (c 0.06, 
MeOH). 
cis-2-[(1-thymin-1-yl-cyclopentan-4-yl)oxy]malonic acid (2) 
Synthesized using procedure described for 2a using: 28 (25 mg, 0.051 mmol) and palladium on 
carbon (10 mg, 10%) to give 2 (9 mg, 57%). 
cis-1-[bis(Diethylphosphono)methoxy]-4-acetoxycyclopent-2-ene (31) 
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cis-4-Hydroxy-2-cyclopentenyl acetate 26 (0.69 g, 4.7 mmol) and tetraethyl 
diazomethylenebisphosphonate 30 (2.95 g, 9.4 mmol) were dissolved in degassed benzene (15 
mL).  Rhodium (II) trifluoroacetamide (30 mg, 1 mol %) was added and the reaction mixture was 
refluxed for 18 h, after which time a second portion (30 mg, 1 mol %) of catalyst was added and 
reflux was continued for a further 24 h and then a third portion (30 mg, 1 mol %) was added and 
reflux was continued for a further 28 h.  After removal of benzene under reduced pressure the 
residue was subjected to flash chromatography (EtOAc to 5% MeOH:95% EtOAc) to afford 
starting material (0.20 g, 29%) then the title bisphosphonate 31 as an oil (1.25 g, 62%); max/cm-1 
2984, 1733, 1237, 1013; 1H NMR (300 MHz, CDCl3) δ: 1.36 (t, J = 7.1, 12H), 1.90 (dt, J = 14.5, 
4.2, 1H), 2.04 (s, 3H), 2.79 (overlapping dt, J = 14.5, 7.4, 1H), 4.11 (t, JPH = 17.6, 1H), 4.13-4.33 
(m, 8H), 4.76-4.85 (m, 1H), 5.44-5.53 (m, 1H), 5.99-6.06 (m, 1H), 6.16-6.23 (m, 1H); 13C NMR 
(75.5 MHz, CDCl3) δ: (75.5 MHz, CDCl3) 16.2-16.5 (m), 21.0, 37.0, 63.2-63.7 (m), 71.8 (t, JPC 
= 157.8), 76.4, 85.6 (t, JPC = 4.7), 133.6, 135.3, 170.6; 31P NMR (121.5 MHz, CDCl3) δ: 15.65, 
15.80 (q, J = 31.7); HRMS (ES+) Exact mass calculated for C16H31O9P2 [M+H]
+ 429.1443; 
found 429.1448. 
cis-1-{4-[bis(Diethylphosphono)methoxy]cyclopent-2-en-1-yl}thymine (32) 
Thymine (95 mg, 0.75 mmol) and sodium carbonate (80 mg, 0.75 mmol) were suspended in 
degassed water (0.8 mL) and degassed acetonitrile (0.8 mL) in a microwave vial and the mixture 
was subjected to microwave irradiation at 50 °C for 30 mins.  Bisphosphonate 31 (270 mg, 0.63 
mmol), Pd(dba)2 (18 mg, 5 mol %) and dppb (27 mg, 10 mol %) were suspended in degassed 
acetonitrile (1 mL), transferred to the microwave vial and the resultant mixture was irradiated at 
50 °C for 30 mins.  TLC analysis showed residual starting material, so a second portion of 
catalysts was added together with more acetonitrile (1 mL) and the reaction mixture was 
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irradiated for a further 30 mins at 50 °C.  After cooling, dichloromethane (5 mL) was added and 
the mixture was filtered through Celite, washed with dichloromethane (20 mL) and the filtrate 
was concentrated under reduced pressure to give a residue which was purified by flash 
chromatography (5-10% MeOH in EtOAc) to afford 32 as a foamy solid (148 mg, 48 %); 
max/cm-1 3169, 2983,  1683, 1251, 1015; 1H NMR (400 MHz, CDCl3) δ: 1.28-1.45 (m, 12H), 
1.86 (dt, J = 15.2, 2.8, 1H), 1.92 (s, 3H), 2.81 (overlapping dt, J = 15.6, 7.9, 1H), 4.14 (t, JPH = 
17.8, 1H), 4.17-4.36 (m, 8H), 4.85-4.93 (m, 1H), 5.63-5.73 (m, 1H), 5.87-5.95 (m, 1H), 6.29-
6.38 (m, 1H), 7.23 (s, 1H), 9.79 (s, 1H); 13C NMR (100.6 MHz, CDCl3) δ: 12.3, 16.0-16.7 (m), 
36.7, 57.8, 63.1-63.6 (m), 72.0 (t, JPC = 158.1), 86.1 (t, JPC = 4.5), 111.2, 134.0, 136.1, 137.2, 
151.2, 164.1;31P NMR (162.0 MHz, CDCl3) δ: 15.72, 15.92 (ABq, JAB = 31.1); HRMS (ES+) 
Exact mass calculated for C19H33N2O9P2 [M+H]
+ 495.1661; found 495.1660. 
 
cis-1-{4-[(Diphosphono)methoxy]cyclopent-2-en-1-yl}thymine (3) 
Bisphosphonate 32 (32 mg, 0.065 mmol) was suspended in acetonitrile (1.5 mL) in a microwave 
vial and 2,6-lutidine (75 µL, 0.64 mmol ) then TMSBr (85 µL, 0.64 mmol) were added.  The 
reaction mixture was irradiated at 50 °C for 30 mins then methanol (1.5 mL) and water (100 µL) 
were added and stirring was continued for 1 h.  Solvents were removed under reduced pressure 
and the residue was subjected to charcoal chromatography, eluting with water then 20% aqueous 
ammonia, to give the title compound as the ammonium salt (22 mg, 84%); 1H NMR (400 MHz, 
D2O) δ: 1.64-1.78 (m, 1H), 1.83 (s, 3H), 2.81-3.02 (m, 1H), 3.67-3.98 (m, 1H), 4.85-4.95 (m, 
1H), 5.36-5.46 (m, 1H), 5.80-5.90 (m, 1H), 6.31-6.42 (m, 1H), 7.49 (s, 1H); 13C NMR (100.6 
MHz, D2O) δ: 11.3, 37.2, 59.1, 84.9-85.1 (m), 111.3, 131.9, 137.3, 140.0, 152.4, 166.8, (PCH 
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not seen); 31P NMR (162.0 MHz, D2O) δ: 13.4; HRMS (ES-) Exact mass calculated for 
C11H15N2O9P2 [M-H]
- 381.0253; found 381.0240. 
cis-1-{4-[bis(Diethylphosphono)methoxy]cyclopentan-1-yl}thymine (33) 
cis-1-{4-[bis(Diethylphosphono)methoxy]cyclopent-2-en-1-yl}thymine (123 mg, 0.25 mmol) 
was dissolved in methanol (10 mL), 5% palladium on carbon (40 mg) was added and the mixture 
was stirred under hydrogen for 17 h then filtered through Celite.  After washing with MeOH ( 2 
x 10 mL) then dichloromethane ( 2 x 10 mL) the filtrate was concentrated under reduced 
pressure and the residue subjected to flash chromatography (1:9, MeOH:EtOAc) to afford the 
title product (106 mg, 86%); max/cm-13171, 2982, 1667, 1240, 1011; 1H NMR (400 MHz, 
CDCl3) δ: 1.31-1.45 (12H, m), 1.49-1.65 (1H, m), 1.77-1.92 (2H, m), 1.98 (3H, s), 2.10-2.23 
(2H, m), 2.33-2.46 (1H, m), 4.04 (t, JPH = 17.6, 1H), 4.15-4.36 (8H, m), 4.41-4.50 (1H, m), 5.15-
5.28 (1H, m), 7.65 (1H, s), 8.81 (1H, s); 13C NMR (100.6 MHz, CDCl3) δ: 12.3, 16.3-16.6 (m), 
30.2, 30.8, 38.3, 53.5, 63.1-63.7 (m), 70.8 (t, JPC = 158.6), 83.4 (t, JPC = 4.2), 111.5, 138.0, 
151.3, 163.7; 31P NMR (162.0 MHz, CDCl3) δ: 16.25, 16.31 (ABq, JAB = 31.2); HRMS (ES+) 
Exact mass calculated for C19H35N2O9P2 [M+H]
+ 497.1818; found 497.1821. 
cis-1-{4-[(Diphosphono)methoxy]cyclopentan-1-yl}thymine (4) 
cis-1-{4-[bis(Diethylphosphono)methoxy]cyclopentan-1-yl}thymine (106 mg, 0.21 mmol) was 
suspended in acetonitrile (2 mL) in a microwave vial and TMSBr (420 µL, 0.64 mmol, 15 eq) 
was added.  The reaction mixture was irradiated at 50 °C for 1 h then methanol (2 mL) and water 
(0.5 mL) were added and stirring was continued for 1 h.  Solvents were removed under reduced 
pressure and the residue was subjected to charcoal chromatography, eluting with water then 20% 
aqueous ammonia, to give the ammonium salt of the title compound as a cream solid (24 mg, 
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29%); max/cm-1 2948, 1655, 1272, 1041; 1H NMR (400 MHz, D2O) δ:  1.62-2.11 (m, 8H), 2.31-
2.51 (1H, m), 3.72 (t, JPH = 13, 1H), 4.31-4.51 (1H, m), 4.80-4.95 (1H, m), 7.84 (1H, s); 13C 
NMR (100.6 MHz, D2O) δ: 11.5, 29.1, 30.0, 37.3, 54.8, 81.1-81.3 (m), 111.3, 140.6, 152.6, 
166.7; 31P NMR (162.0 MHz, D2O) δ: 13.76, 13.96; MS (ES+) m/z: 407 (M + Na)+; HRMS (ES-
) Exact mass calculated for C11H17N2O9P2 [M-H]
- 383.0409; found 383.0402. 
cis-1-{4-[(Aminocarbonyl)dimethylphosphonomethoxy]cyclopentan-1-yl}thymine (35) 
cis-1-{4-[(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopentan-1-yl}thymine 34 (155 
mg, 0.40 mmol) was dissolved in 7N ammonia in methanol (20 mL, 140 mmol).  The flask was 
tightly stoppered and the solution stirred at RT for 65 h.  After concentration under reduced 
pressure, flash chromatography (1:9, MeOH:CH2Cl2) afforded 35 as a white solid as an 
essentially equimolar mixture of two diastereomers (52 mg, 35%); max/cm-1 3188, 2958, 1661, 
1247, 1026, 727; 1H NMR (400 MHz, CDCl3) δ: 1.56-2.24 (m, 8H), 2.35-2.50 (m, 1H), 3.80-
3.93 (m, 6H), 4.18-4.26 (m, 1H), 4.32 (2 overlapping d which appear as a t, JPH = 18.8), 5.00-
5.22 (m, 1H), 6.67-6.78 (br s, 1H), 6.94 (br s, 0.5H), 7.06 (br s, 0.5H), 7.55 (s, 0.5H), 7.57 (s, 
0.5H), 9.95 (br s, 1H); 13C NMR (100.6 MHz, CDCl3) δ: 12.29, 12.33, 29.6, 30.4, 31.6, 37.4, 
38.5,  53.5, 54.39,  53.8 (d, JPC = 6.8), 54.0 (d, JPC = 6.8), 54.2 (d, JPC = 6.8), 54.3 (d, JPC = 6.9), 
74.1 (d, JPC = 158.1), 75.3 (d, JPC = 157.3), 81.8 (d, JPC = 10.8), 82.7 (d, JPC = 8.8), 111.4, 111.5, 
137.91, 137.93, 151.49, 151.55, 164.2, 169.07 (d, JPC = 3.0), 169.35 (d, JPC = 3.3); 
31P NMR 
(162.0 MHz, CDCl3) δ: 18.47, 18.65; HRMS (ES+) Exact mass calculated for C14H23N3O7P 
[M+H]+ 376.1274; found 376.1265. 
cis-1-{4-[(Aminocarbonyl)phosphonomethoxy]cyclopentan-1-yl}thymine (5) 
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cis-1-{4-[(Aminocarbonyl)dimethylphosphonomethoxy]cyclopentan-1-yl}thymine 35 (66 mg, 
0.17 mmol) was suspended in acetonitrile (2 mL) in a microwave vial and TMSBr (93 µL, 0.70 
mmol) was added.  The reaction mixture was irradiated at 50 °C for 10 mins then methanol (1.9 
mL) and water (100 µL) were added and stirring was continued for 10 minutes. Solvents were 
removed under reduced pressure and the residue was subjected to charcoal chromatography, 
eluting with water then 10:10:3, H2O:MeOH:20% aq NH3 to afford the ammonium salt of 5 as a 
fawn solid (45 mg, 70%); max/cm-1 3186, 2957, 1561, 1270, 1055, 765; 1H NMR (400 MHz, 
D2O) δ: 1.52-2.01 (m, 8H), 2.19-2.39 (m, 1H), 3.91 (2 overlapping d which appear as a t, JPH = 
17.2), 4.01 (br s, 1H), 4.66-4.85 (m, 1H), 7.61 (s, 0.5H), 7.64 (s, 0.5H); 13C NMR (100.6 MHz, 
D2O) δ: 11.46, 11.49, 28.7, 28.9, 29.7, 30.5, 36.5, 37.4, 54.7, 55.0, 77.4 (d, JPC = 138.3), 78.0 (d, 
JPC = 138.7), 80.6 (d, JPC = 9.2), 81.1 (d, JPC = 8.8), 111.2, 111.3, 140.1, 140.2, 152.49, 152.51, 
166.49, 166.52, 175.8, 176.0; 31P NMR (162.0 MHz, D2O) δ: 9.7 br; HRMS (ES+) Exact mass 
calculated for C12H19N3O7P [M+H]
+ 348.0961; found 348.0953. 
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